Pan-Cancer (N=930) | HB-Cancer (N=1151) | Pan-disease (N=4409) | HB-disease (N=21002) | Control (N=5895) | Total (N=33387) | p value | |
---|---|---|---|---|---|---|---|
Gender | < 0.0011 | ||||||
   Female | 439 (47.2%) | 430 (37.4%) | 2043 (46.3%) | 11186 (53.3%) | 1681 (28.5%) | 15779 (47.3%) | |
   Male | 491 (52.8%) | 721 (62.6%) | 2366 (53.7%) | 9816 (46.7%) | 4214 (71.5%) | 17608 (52.7%) | |
Ethnicity | < 0.0011 | ||||||
   White | 519 (66.6%) | 549 (53.7%) | 2370 (57.6%) | 10396 (51.5%) | 3280 (57.7%) | 17114 (53.9%) | |
   South Asian | 79 (10.1%) | 230 (22.5%) | 874 (21.2%) | 5207 (25.8%) | 942 (16.6%) | 7332 (23.1%) | |
   Black | 98 (12.6%) | 121 (11.8%) | 408 (9.9%) | 2046 (10.1%) | 806 (14.2%) | 3479 (10.9%) | |
   Far/South-east Asian | 4 (0.5%) | 24 (2.3%) | 19 (0.5%) | 234 (1.2%) | 31 (0.5%) | 312 (1.0%) | |
   Arab/North African | 0 (0.0%) | 0 (0.0%) | 1 (0.0%) | 15 (0.1%) | 5 (0.1%) | 21 (0.1%) | |
   Asian (Other) | 17 (2.2%) | 46 (4.5%) | 178 (4.3%) | 970 (4.8%) | 234 (4.1%) | 1445 (4.5%) | |
   Mixed | 9 (1.2%) | 8 (0.8%) | 49 (1.2%) | 241 (1.2%) | 78 (1.4%) | 385 (1.2%) | |
   Other | 53 (6.8%) | 45 (4.4%) | 217 (5.3%) | 1065 (5.3%) | 306 (5.4%) | 1686 (5.3%) | |
Diagnosis age (years) | < 0.0012 | ||||||
   Mean (SD) | 66.91 (12.72) | 65.24 (13.22) | 52.90 (18.51) | 53.64 (17.67) | 54.77 (17.59) | 54.51 (17.77) | |
   Median | 67.21 | 66.06 | 51.28 | 52.42 | 54.09 | 53.62 | |
   Q1,Q3 | 58.88, 76.07 | 56.79, 75.15 | 38.36, 67.20 | 39.90, 66.40 | 41.02, 68.00 | 40.66, 67.85 | |
Diagnosis age group | < 0.0011 | ||||||
   18-40 | 27 (2.9%) | 54 (4.7%) | 1318 (29.9%) | 5663 (27.0%) | 1470 (24.9%) | 8532 (25.6%) | |
   41-50 | 66 (7.1%) | 100 (8.7%) | 862 (19.6%) | 4149 (19.8%) | 1097 (18.6%) | 6274 (18.8%) | |
   51-60 | 189 (20.3%) | 266 (23.1%) | 773 (17.5%) | 4186 (19.9%) | 1163 (19.7%) | 6577 (19.7%) | |
   61-70 | 290 (31.2%) | 325 (28.2%) | 574 (13.0%) | 3022 (14.4%) | 961 (16.3%) | 5172 (15.5%) | |
   71-80 | 234 (25.2%) | 273 (23.7%) | 519 (11.8%) | 2311 (11.0%) | 733 (12.4%) | 4070 (12.2%) | |
   >80 | 124 (13.3%) | 133 (11.6%) | 363 (8.2%) | 1671 (8.0%) | 471 (8.0%) | 2762 (8.3%) | |
Mortality | < 0.0011 | ||||||
   Deceased | 754 (81.1%) | 795 (69.1%) | 840 (19.1%) | 3634 (17.3%) | 614 (10.4%) | 6637 (19.9%) | |
   Survived | 176 (18.9%) | 356 (30.9%) | 3569 (80.9%) | 17368 (82.7%) | 5281 (89.6%) | 26750 (80.1%) | |
Survival (months) | < 0.0012 | ||||||
   Mean (SD) | 15.88 (24.91) | 22.37 (29.54) | 49.69 (64.39) | 58.03 (77.33) | 57.50 (71.17) | 54.43 (73.08) | |
   Median | 8.05 | 12.47 | 28.93 | 34.87 | 36.57 | 32.20 | |
   Q1,Q3 | 2.58, 18.18 | 3.52, 29.40 | 9.60, 66.17 | 12.50, 73.46 | 14.57, 71.95 | 11.07, 69.57 |
HB-Cancer (N=1151) | Control (N=5895) | Total (N=7046) | p value | |
---|---|---|---|---|
Gender | < 0.0011 | |||
   Female | 430 (37.4%) | 1681 (28.5%) | 2111 (30.0%) | |
   Male | 721 (62.6%) | 4214 (71.5%) | 4935 (70.0%) | |
Ethnicity | < 0.0011 | |||
   White | 549 (53.7%) | 3280 (57.7%) | 3829 (57.1%) | |
   South Asian | 230 (22.5%) | 942 (16.6%) | 1172 (17.5%) | |
   Black | 121 (11.8%) | 806 (14.2%) | 927 (13.8%) | |
   Far/South-east Asian | 24 (2.3%) | 31 (0.5%) | 55 (0.8%) | |
   Arab/North African | 0 (0.0%) | 5 (0.1%) | 5 (0.1%) | |
   Asian (Other) | 46 (4.5%) | 234 (4.1%) | 280 (4.2%) | |
   Mixed | 8 (0.8%) | 78 (1.4%) | 86 (1.3%) | |
   Other | 45 (4.4%) | 306 (5.4%) | 351 (5.2%) | |
Diagnosis age (years) | < 0.0012 | |||
   Mean (SD) | 65.24 (13.22) | 54.77 (17.59) | 56.48 (17.39) | |
   Median | 66.06 | 54.09 | 56.76 | |
   Q1,Q3 | 56.79, 75.15 | 41.02, 68.00 | 43.09, 69.63 | |
Diagnosis age group | < 0.0011 | |||
   18-40 | 54 (4.7%) | 1470 (24.9%) | 1524 (21.6%) | |
   41-50 | 100 (8.7%) | 1097 (18.6%) | 1197 (17.0%) | |
   51-60 | 266 (23.1%) | 1163 (19.7%) | 1429 (20.3%) | |
   61-70 | 325 (28.2%) | 961 (16.3%) | 1286 (18.3%) | |
   71-80 | 273 (23.7%) | 733 (12.4%) | 1006 (14.3%) | |
   >80 | 133 (11.6%) | 471 (8.0%) | 604 (8.6%) | |
Mortality | < 0.0011 | |||
   Deceased | 795 (69.1%) | 614 (10.4%) | 1409 (20.0%) | |
   Survived | 356 (30.9%) | 5281 (89.6%) | 5637 (80.0%) | |
Survival (months) | < 0.0012 | |||
   Mean (SD) | 22.37 (29.54) | 57.50 (71.17) | 51.76 (67.44) | |
   Median | 12.47 | 36.57 | 31.45 | |
   Q1,Q3 | 3.52, 29.40 | 14.57, 71.95 | 11.13, 66.46 |
HB-Cancer (N=1151) | Control (N=5895) | Total (N=7046) | p value | |
---|---|---|---|---|
Comorbidity | < 0.0011 | |||
   Mean (SD) | 3.46 (2.20) | 1.92 (1.87) | 2.17 (2.01) | |
   Median | 3.00 | 1.00 | 2.00 | |
   Q1,Q3 | 2.00, 5.00 | 0.00, 3.00 | 0.00, 4.00 | |
Diabetes | 427 (37.1%) | 1010 (17.1%) | 1437 (20.4%) | < 0.0012 |
Hypertension | 698 (60.6%) | 2545 (43.2%) | 3243 (46.0%) | < 0.0012 |
Cholesterol | 533 (46.3%) | 2226 (37.8%) | 2759 (39.2%) | < 0.0012 |
Asthma | 133 (11.6%) | 874 (14.8%) | 1007 (14.3%) | 0.0042 |
COPD | 87 (7.6%) | 306 (5.2%) | 393 (5.6%) | 0.0012 |
TB | 19 (1.7%) | 67 (1.1%) | 86 (1.2%) | 0.1462 |
Kidney | 226 (19.6%) | 821 (13.9%) | 1047 (14.9%) | < 0.0012 |
Cardiovascular | 333 (28.9%) | 1362 (23.1%) | 1695 (24.1%) | < 0.0012 |
Upper GI | 436 (37.9%) | 1287 (21.8%) | 1723 (24.5%) | < 0.0012 |
Lower GI | 129 (11.2%) | 682 (11.6%) | 811 (11.5%) | 0.7252 |
F/H: Cancer | 154 (13.4%) | 1141 (19.4%) | 1295 (18.4%) | < 0.0012 |
F/H: Digestive | 41 (3.6%) | 120 (2.0%) | 161 (2.3%) | 0.0022 |
F/H: Diabetes | 234 (20.3%) | 1484 (25.2%) | 1718 (24.4%) | < 0.0012 |
HB-Cancer (N=1151) | Control (N=5895) | Total (N=7046) | p value | |
---|---|---|---|---|
Smoker | < 0.0011 | |||
   Not available | 246 (21.4%) | 481 (8.2%) | 727 (10.3%) | |
   Never | 362 (31.5%) | 2278 (38.6%) | 2640 (37.5%) | |
   Past | 322 (28.0%) | 1767 (30.0%) | 2089 (29.6%) | |
   Current | 221 (19.2%) | 1369 (23.2%) | 1590 (22.6%) | |
Drinker | < 0.0011 | |||
   Not available | 407 (35.4%) | 1228 (20.8%) | 1635 (23.2%) | |
   Never | 217 (18.9%) | 1340 (22.7%) | 1557 (22.1%) | |
   Past | 75 (6.5%) | 291 (4.9%) | 366 (5.2%) | |
   Current | 452 (39.3%) | 3036 (51.5%) | 3488 (49.5%) | |
Substance user | < 0.0011 | |||
   Not available | 665 (57.8%) | 2739 (46.5%) | 3404 (48.3%) | |
   Never | 189 (16.4%) | 2117 (35.9%) | 2306 (32.7%) | |
   Past | 11 (1.0%) | 37 (0.6%) | 48 (0.7%) | |
   Current | 286 (24.8%) | 1002 (17.0%) | 1288 (18.3%) | |
Obese | < 0.0011 | |||
   Not available | 218 (18.9%) | 540 (9.2%) | 758 (10.8%) | |
   Never | 211 (18.3%) | 1269 (21.5%) | 1480 (21.0%) | |
   Past | 478 (41.5%) | 2539 (43.1%) | 3017 (42.8%) | |
   Current | 244 (21.2%) | 1547 (26.2%) | 1791 (25.4%) |
HB-Cancer (N=828) | Control (N=5074) | Total (N=5902) | p value | |
---|---|---|---|---|
Gender | < 0.0011 | |||
   Female | 305 (36.8%) | 1457 (28.7%) | 1762 (29.9%) | |
   Male | 523 (63.2%) | 3617 (71.3%) | 4140 (70.1%) | |
Ethnicity | < 0.0011 | |||
   White | 405 (49.5%) | 2788 (55.5%) | 3193 (54.6%) | |
   South Asian | 210 (25.7%) | 898 (17.9%) | 1108 (19.0%) | |
   Black | 107 (13.1%) | 755 (15.0%) | 862 (14.8%) | |
   Far/South-east Asian | 23 (2.8%) | 29 (0.6%) | 52 (0.9%) | |
   Arab/North African | 0 (0.0%) | 5 (0.1%) | 5 (0.1%) | |
   Asian (Other) | 37 (4.5%) | 219 (4.4%) | 256 (4.4%) | |
   Mixed | 7 (0.9%) | 71 (1.4%) | 78 (1.3%) | |
   Other | 29 (3.5%) | 260 (5.2%) | 289 (4.9%) | |
Diagnosis age (years) | < 0.0012 | |||
   Mean (SD) | 64.49 (13.64) | 53.84 (17.18) | 55.34 (17.13) | |
   Median | 65.05 | 53.14 | 55.30 | |
   Q1,Q3 | 55.28, 74.80 | 40.29, 66.68 | 41.96, 68.23 | |
Diagnosis age group | < 0.0011 | |||
   18-40 | 45 (5.4%) | 1326 (26.1%) | 1371 (23.2%) | |
   41-50 | 77 (9.3%) | 991 (19.5%) | 1068 (18.1%) | |
   51-60 | 210 (25.4%) | 1010 (19.9%) | 1220 (20.7%) | |
   61-70 | 222 (26.8%) | 820 (16.2%) | 1042 (17.7%) | |
   71-80 | 176 (21.3%) | 581 (11.5%) | 757 (12.8%) | |
   >80 | 98 (11.8%) | 346 (6.8%) | 444 (7.5%) | |
Mortality | < 0.0011 | |||
   Deceased | 545 (65.8%) | 483 (9.5%) | 1028 (17.4%) | |
   Survived | 283 (34.2%) | 4591 (90.5%) | 4874 (82.6%) | |
Survival (months) | < 0.0012 | |||
   Mean (SD) | 24.85 (32.28) | 64.21 (73.97) | 58.69 (70.97) | |
   Median | 14.40 | 42.40 | 37.37 | |
   Q1,Q3 | 4.35, 33.26 | 19.81, 78.11 | 16.31, 72.93 |
HB-Cancer (N=828) | Control (N=5074) | Total (N=5902) | p value | |
---|---|---|---|---|
Comorbidity | < 0.0011 | |||
   Mean (SD) | 4.02 (2.15) | 1.99 (1.92) | 2.27 (2.08) | |
   Median | 4.00 | 2.00 | 2.00 | |
   Q1,Q3 | 2.00, 6.00 | 0.00, 3.00 | 0.00, 4.00 | |
Diabetes | 345 (41.7%) | 884 (17.4%) | 1229 (20.8%) | < 0.0012 |
Hypertension | 572 (69.1%) | 2183 (43.0%) | 2755 (46.7%) | < 0.0012 |
Cholesterol | 478 (57.7%) | 2065 (40.7%) | 2543 (43.1%) | < 0.0012 |
Asthma | 116 (14.0%) | 783 (15.4%) | 899 (15.2%) | 0.2912 |
COPD | 72 (8.7%) | 237 (4.7%) | 309 (5.2%) | < 0.0012 |
TB | 18 (2.2%) | 66 (1.3%) | 84 (1.4%) | 0.0492 |
Kidney | 186 (22.5%) | 679 (13.4%) | 865 (14.7%) | < 0.0012 |
Cardiovascular | 275 (33.2%) | 1131 (22.3%) | 1406 (23.8%) | < 0.0012 |
Upper GI | 410 (49.5%) | 1266 (25.0%) | 1676 (28.4%) | < 0.0012 |
Lower GI | 121 (14.6%) | 653 (12.9%) | 774 (13.1%) | 0.1682 |
F/H: Cancer | 154 (18.6%) | 1141 (22.5%) | 1295 (21.9%) | 0.0122 |
F/H: Digestive | 38 (4.6%) | 116 (2.3%) | 154 (2.6%) | < 0.0012 |
F/H: Diabetes | 234 (28.3%) | 1482 (29.2%) | 1716 (29.1%) | 0.5782 |
HB-Cancer (N=828) | Control (N=5074) | Total (N=5902) | p value | |
---|---|---|---|---|
Smoker | 0.1261 | |||
   Not available | 6 (0.7%) | 16 (0.3%) | 22 (0.4%) | |
   Never | 331 (40.0%) | 2130 (42.0%) | 2461 (41.7%) | |
   Past | 297 (35.9%) | 1685 (33.2%) | 1982 (33.6%) | |
   Current | 194 (23.4%) | 1243 (24.5%) | 1437 (24.3%) | |
Drinker | < 0.0011 | |||
   Not available | 154 (18.6%) | 674 (13.3%) | 828 (14.0%) | |
   Never | 183 (22.1%) | 1204 (23.7%) | 1387 (23.5%) | |
   Past | 74 (8.9%) | 288 (5.7%) | 362 (6.1%) | |
   Current | 417 (50.4%) | 2908 (57.3%) | 3325 (56.3%) | |
Substance user | < 0.0011 | |||
   Not available | 444 (53.6%) | 2237 (44.1%) | 2681 (45.4%) | |
   Never | 148 (17.9%) | 1965 (38.7%) | 2113 (35.8%) | |
   Past | 11 (1.3%) | 33 (0.7%) | 44 (0.7%) | |
   Current | 225 (27.2%) | 839 (16.5%) | 1064 (18.0%) | |
Obese | 0.0511 | |||
   Not available | 21 (2.5%) | 101 (2.0%) | 122 (2.1%) | |
   Never | 166 (20.0%) | 1174 (23.1%) | 1340 (22.7%) | |
   Past | 428 (51.7%) | 2400 (47.3%) | 2828 (47.9%) | |
   Current | 213 (25.7%) | 1399 (27.6%) | 1612 (27.3%) |